Oncogenic potential of bifunctional bioreductive drugs

British Journal of Cancer

Volumn 74, Issue SUPPL. XXVII, 1996, Pages

  Hei, T K ^a   Liu, S X ^a   Hall, E J ^a  

^a Columbia University ^*  (United States)

Author keywords

Bioreductive drug; Heterocyclic N oxide; Hypoxic toxicity; Oncogenicity; One electron reduction; RB 90740

Indexed keywords

DRUG METABOLITE; HETEROCYCLIC COMPOUND; MITOMYCIN C; OXIDE; PYRAZINE DERIVATIVE; RB 90740; RB 92816; UNCLASSIFIED DRUG; 5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; ANTINEOPLASTIC AGENT; AZIRIDINE DERIVATIVE; INDOLE DERIVATIVE; MITOMYCIN;

AIR; ANIMAL CELL; CELL CULTURE; CELL SURVIVAL; CELL TRANSFORMATION; CONFERENCE PAPER; CYTOTOXICITY; DRUG CARCINOGENICITY; DRUG CYTOTOXICITY; EMBRYO; HYPOXIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; ANIMAL; ARTICLE; C3H MOUSE; DRUG EFFECT; OXIDATION REDUCTION REACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; AZIRIDINES; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; INDOLEQUINONES; INDOLES; MICE; MICE, INBRED C3H; MITOMYCIN; OXIDATION-REDUCTION; PYRAZINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0029976681     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. ADAMS GE AND STRATFORD IJ. (1994). Bioreductive drugs for cancer therapy: the search for tumor specificity. Int. J. Radiat. Oncol. Biol. Phys., 29, 231-238.
2. BACHUR NR, GORDON SL AND GEE MVA. (1978). A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res., 38, 1745-1750.
3. COLEMAN N. (1982). Secondary neoplasms in patients treated for cancer: etiology and perspective. Radiat. Res., 92, 188-200.
4. FRAZELLE JH, ALBERNETHY DJ AND BOREIKO CJ. (1984). Enhanced sensitivity of the C3H 10T1/2 cells transformation system to alkylating and chemotherapeutic agents by treatment with TPA. Environ. Mutagen., 6, 81-89.
5. HALL EJ AND HEI TK. (1990). Modulating factors in the expression of radiation induced oncogenic transformation. Environ. Health Perspective, 88, 149-155.
6. HEI TK, HE ZY, PIAO CQ AND HALL EJ. (1990). Studies with bifunctional bioreductive drugs I. In vitro oncogenic transforming potential. Radiat. Res., 124, S44-S49.
7. HEI TK, PIAO CQ, HE ZY AND HALL EJ. (1992). Mechanism of oncogenicity for bioreductive drugs. Int. J. Radiat. Oncol. Biol. Phys., 22, 747-750.
8. HENDERSON IC AND GELMAN R. (1987). Second malignancies from adjuvant chemotherapy. J. Clin. Oncol., 5, 1135-1137.
9. HENDRIKS HR, PIZAO PE, BERGER DP, KOOISTRA KL, BIBBY MC, BOVEN E, DREEF-VAN DER MEULEN HC, HENRAR REC, FIEBIG HH, DOUBLE JA, HORNSTRA HW, PINEDO HM, WORKMAN P AND SCHWARTSMANN G. (1993). E09: A novel bioreductive alkylating indoloquinone with preferential solid tumor activity and lack of bone marrow toxicity in preclinical models. Eur. J. Cancer, 6, 897-906.
10. KENNEDY AR AND LITTLE JB. (1984). Evidence that a second event in X-ray induced oncogenic transformation in vitro occurred during cellular proliferation. Radiat. Res., 99, 228-248.
11. LANGMUIR VK, LADEROUTE KR, MENDONCA HL, SUTHERLAND RM, HEI TK, LIU SX, HALL EJ, NAYLOR MA AND ADAMS GE. (1996). Fused pyrazine mono-N-oxides as bioreductive drugs. II. Cytotoxicity in human cells and oncogenicity in rodent transformation assay. Int. J. Radiat. Oncol. Biol. Phys., 34, 79-84.
12. NAYLOR MA, SUTTON BM, NOLAN J, O'NEILL P, FIELDEN EM, ADAMS GE AND STRATFORD IJ. (1994). Radiolytic and photochemical reduction of the hypoxic cytotoxin 1,2-dihydro-8-(4-methylpiperazinyl)-4-phenylimidazo [1,2-α] pyridopyrazine-5 oxide (RB 90740) and a potential mechanism for hypoxia selective toxicity. Int. J. Radiat. Oncol. Biol. Phys., 29, 333-337.
13. NAYLOR MA, ADAMS GE, HAIGH A, COLE S, JENNER T, NAOMI R, SIEMANN D, STEPHENS MA AND STRATFORD IA. (1995). Fused pyrazine mon-N-oxides as bio-reductive drugs III. Characteristics of RB 90740 in vitro and in vivo. Anticancer Drugs, 6, 259-269.
14. REZNIKOFF CA, BERTRAM JS, BRANKOW DW AND HEIDELBERGER C. (1973). Quantitative and qualitative studies of chemical transformation of clonal C3H mouse embryo cells sensitive to post-confluence inhibition of cell division. Cancer Res., 33, 3229-3249.
15. WALTON MI, SUGGET N AND WORKMAN P. (1992). The role of human and rodent DT-diaphorase in the reductive metabolism of hypoxic cell cytotoxins. Int. J. Radiat. Oncol. Bio. Phys., 22, 643-647.
16. WORKMAN P. (1992). Keynote address: bioreductive mechanisms. Int. J. Radiat. Oncol. Bio. Phys., 22, 631-637.
17. WORKMAN P, WALTON MI, POWIS G AND SCHLAGER JJ. (1989). DT-Diaphorase: questionable role in mitomycin C resistance, but a target for novel bioreductive drugs. Br. J. Cancer, 60, 800-802.